Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (34)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Morris, S. T. W.
Right arrow Articles by Jardine, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morris, S. T. W.
Right arrow Articles by Jardine, A. G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2000) 15: 1194-1200
© 2000 European Renal Association-European Dialysis and Transplant Association

Impaired endothelium-dependent vasodilatation in uraemia

Scott T. W. Morris1,, John J. V. McMurray2, R. Stuart C. Rodger1 and Alan G. Jardine1

1 The Renal Unit and 2 Department of Cardiology, Western Infirmary, Glasgow, UK

Background. Patients with chronic renal failure (CRF) have a substantially increased risk of cardiovascular death, the proposed mechanisms being arrhythmias (left ventricular hypertrophy) and accelerated atherosclerosis. The vascular endothelium protects against the development of atherosclerosis principally by releasing vasoactive substances such as nitric oxide (NO) and endothelium-derived hyperpolarizing factor. In CRF there is accumulation of endogenous inhibitors of NO synthesis. In this present study we assessed endothelium-dependent vasodilatation in patients with advanced uraemia.

Methods. Sixteen uraemic patients (pre-dialysis and continuous ambulatory peritoneal dialysis) and 18 controls were studied. Forearm plethysmography was used to measure forearm blood flow and the changes induced by carbachol (endothelium-dependent vasodilator) and sodium nitroprusside (SNP; endothelium-independent vasodilator). The order of drugs infused was randomized between subjects. Dose response curves were constructed for each agent and area under the curve (AUC) calculated (arbitrary units).

Results. Overall, vasodilatation to SNP and carbachol was similar between uraemic patients and controls. However, it became apparent that there was a marked order effect for the drugs infused, such that infusion of SNP as the first agent blunted the subsequent response to carbachol. When only those patients and controls who received carbachol followed by SNP were studied (10 in each group), the response to carbachol in uraemic patients was attenuated compared to controls: AUC (median(range)) for uraemic patients 529.0 (150.9–834.7) compared to AUC for controls 703.9 (583.5–1576.6); P=0.028. Vasodilatation to SNP was, however, similar between groups: AUC for uraemic patients 1475.0 (857.8–4717.1) compared to AUC for controls 1328.1 (216.6–3311.4); P=0.545.

Conclusions. This study has demonstrated a marked drug order effect not previously described for forearm plethysmography. When the order effect was taken into account, this study demonstrated reduced vasodilatation to carbachol in uraemic patients with a preserved response to SNP. This pattern indicates impaired endothelium-dependent vasodilatation in uraemic patients, a defect that may predispose this group to accelerated atherosclerosis.

Keywords: cardiovascular disease; forearm plethysmography; hypertension; nitric oxide; uraemia; vascular endothelium

Correspondence and offprint requests to: Dr Scott Morris, Renal Unit, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Therapeutic Advances in Respiratory DiseaseHome page
M. Yigla, R. Banderski, Z. S. Azzam, S. A. Reisner, and F. Nakhoul
Arterio-venous access in end-stage renal disease patients and pulmonary hypertension
Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 49 - 53.
[Abstract] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J.-P. Stasch, P.M. Schmidt, P.I. Nedvetsky, T.Y. A. Nedvetskaya, H.S. Kumar, S. Meurer, M. Deile, A. Taye, A. Knorr, H. Lapp, et al.
Endothelial Cell Dysfunction--Can One Outsmart Oxidative Stress by Direct Interaction with the Pathological Oxidized or Heme-Free Soluble Guanyl-Cyclase?: Targeting the Heme-Oxydized Nitric Oxide Receptor for Selective Vasodilatation of Diseased Blood Vessels. J Clin Invest 116: 2552-2561, 2006
J. Am. Soc. Nephrol., March 1, 2007; 18(3): 663 - 669.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
K. Farkas, J. Nemcsik, E. Kolossvary, Z. Jarai, E. Nadory, C. Farsang, and I. Kiss
Impairment of skin microvascular reactivity in hypertension and uraemia
Nephrol. Dial. Transplant., September 1, 2005; 20(9): 1821 - 1827.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
F. Mittermayer, G. Schaller, J. Pleiner, A. Vychytil, G. Sunder-Plassmann, W. H. Horl, and M. Wolzt
Asymmetrical Dimethylarginine Plasma Concentrations Are Related to Basal Nitric Oxide Release but Not Endothelium-Dependent Vasodilation of Resistance Arteries in Peritoneal Dialysis Patients
J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1832 - 1838.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. S. Goligorsky
Endothelial cell dysfunction: can't live with it, how to live without it
Am J Physiol Renal Physiol, May 1, 2005; 288(5): F871 - F880.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Stewart, A. Kohen, D. Brouder, F. Rahim, S. Adler, R. Garrick, and M. S. Goligorsky
Noninvasive interrogation of microvasculature for signs of endothelial dysfunction in patients with chronic renal failure
Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2687 - H2696.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
K. Amann, M.-L. Gross, and E. Ritz
Pathophysiology Underlying Accelerated Atherogenesis in Renal Disease: Closing in on the Target
J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1664 - 1666.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Tepel
Oxidative stress: does it play a role in the genesis of essential hypertension and hypertension of uraemia?
Nephrol. Dial. Transplant., August 1, 2003; 18(8): 1439 - 1442.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Tepel
Oxidative stress: does it play a role in the genesis of essential hypertension and hypertension of uraemia?
Nephrol. Dial. Transplant., August 1, 2003; 18(88): 1439 - 1442.
[Full Text]


Home page
HypertensionHome page
P. Koobi, J. Kalliovalkama, P. Jolma, J. Rysa, H. Ruskoaho, O. Vuolteenaho, M. Kahonen, I. Tikkanen, M. Fan, P. Ylitalo, et al.
AT1 Receptor Blockade Improves Vasorelaxation in Experimental Renal Failure
Hypertension, June 1, 2003; 41(6): 1364 - 1371.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.